OncoSec Medical Incorporated (ONCSQ)

Market Cap	60.00 +900.0%
Revenue (ttm)	n/a
Net Income	-29.39M
EPS	-14.77
Shares Out	5.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	555
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	13.84
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About OncoSec Medical

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 41
• Stock Exchange: OTCMKTS
• Ticker Symbol: ONCSQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error